Body mass index influences the response to infliximab in ankylosing spondylitis

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Ottaviani, Sébastien ^a   Allanore, Yannick ^b,c   Tubach, Florence ^d   Forien, Marine ^a   Gardette, Anaïs ^a   Pasquet, Blandine ^c   Palazzo, Elisabeth ^a   Meunier, Marine ^b   Hayem, Gilles ^a   Job Deslandre, Chantal ^b   Kahan, André ^b   Meyer, Olivier ^a   Dieudé, Philippe ^a,d  

^a Paris Descartes University   (France)

^b Cochin Hospital ^*  (France)

^c INSTITUT COCHIN   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VISUAL ANALOG SCALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84860806992     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3841     Document Type: Article

References (27)

1. WHO Library Cataloging-in-Publication data Obesity: preventing and managing the global epidemic. Technical Report Series 894 2000, WHO Library Cataloging-in-Publication data., http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/
2. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010, 49:71-87. 10.2165/11318100-000000000-00000, 20067334.
3. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783. 10.1038/nri1937, 16998510.
4. Muller-Ladner U, Neumann E. Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol 2009, 5:659-660. 10.1038/nrrheum.2009.232, 19946293.
5. Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis: possible association with tumor necrosis factor. J Rheumatol 1992, 19:1505-1510.
6. Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008, 35:855-861.
7. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011, 63:359-364. 10.1002/art.30136, 21279992.
8. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, Veys E, Zeidler H. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227. 10.1002/art.1780341003, 1930310.
9. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824. 10.1136/ard.62.9.817, 1754665, 12922952.
10. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011, 70:973-981. 10.1136/ard.2010.147744, 3086037, 21402563.
11. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:563-570.
12. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986, 172:298-304. 10.1159/000249365, 3089849.
13. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: evidence from the Psocare project. Dermatology 2008, 217:365-373. 10.1159/000156599, 18810241.
14. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011, 25:1007-1011. 10.1111/j.1468-3083.2011.04065.x, 21492252.
15. Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008, 57:290-295. 10.1016/j.phrs.2008.02.006, 18400510.
16. Wiese D, Lashner B, Seidner D. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract 2008, 23:551-556. 10.1177/0884533608323421, 18849561.
17. Nakahigashi M, Yamamoto T. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study. Cytokine 2011, 56:531-535. 10.1016/j.cyto.2011.07.013, 21820319.
18. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665-670. 10.1136/ard.2003.016386, 1755042, 15037444.
19. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. 10.1002/art.20852, 15692973.
20. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459. 10.1002/art.10302, 12115174.
21. Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, Henry YD, Barbey C, Trappe G, Dougados M, Emilie D. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009, 61:569-576. 10.1002/art.24275, 19405015.
22. Villela NR, Kramer-Aguiar LG, Bottino DA, Wiernsperger N, Bouskela E. Metabolic disturbances linked to obesity: the role of impaired tissue perfusion. Arq Bras Endocrinol Metab 2009, 53:238-245.
23. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN. Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fund Clin Pharmacol 2009, 23:595-600.
24. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T, Minami H, Sasaki Y. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001, 19:61-67. 10.1023/A:1006456717846, 11291833.
25. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?. J Hypertens 2001, 19:667-674. 10.1097/00004872-200104000-00001, 11330867.
26. Cortinez LI, Anderson BJ, Penna A, Olivares L, Munoz HR, Holford NH, Struys MM, Sepulveda P. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010, 105:448-456. 10.1093/bja/aeq195, 20710020.
27. Ferraccioli G, Trotta F, Punzi L, Ferri C, Sarzi-Puttini P, Bambara L, Triolo G, Giacomelli R, Gerli R, Gorla R, Marchesoni A, Grassi W, Lapadula G. Weight and response to biologics in RA and spondylarthritides: obesity reduces the rate of remission-response: The GISEA Registry [Abstract]. Arthritis Rheum 2010, 62:297.